Bob Geho's guest appearances

Bob Geho

Empowered Patient Podcast

Solebury Trout Talks

Brian Culley

Ralph Kern

Matt Murphy

Robin Smith

Thomas Cowan

Greg Miller

Travis Mickle

Justin Miller

Srinivas Rao

Sean Tucker

Matt Wilson

Chris Young

Jim Martin

Peter Hotez

Robin Zander

OwlTail

Mr. Geho has twenty-five years of experience in the field of diabetes drug development and is a recognized leader in the industry’s effort to develop novel insulin therapies for people with Type 1 and Type 2 diabetes.  As a patient-entrepreneur, he has been a dedicated team member and leader in the execution of more than twenty different human clinical studies designed to test various forms of both injected and oral insulins for diabetes, including the first ever Phase 2b study of oral liver targeted insulin and the first ever Phase 2b study of injected liver targeted mealtime insulin.In his role at Diasome, he is responsible for aligning technology, clinical, and business teams in Diasome’s work to achieve the first approved liver targeted insulin therapy. Mr. Geho received his undergraduate degree from both The Cleveland Institute of Music and Case Western Reserve University and his MBA from The Weatherhead School of Management at CWRU.

Mr. Geho has twenty-five years of experience in the field of diabetes drug development and is a recognized leader in the industry’s effort to develop novel insulin therapies for people with Type 1 and Type 2 diabetes. As a patient-entrepreneur, he has been a dedicated team member and leader in the execution of more than twenty different human clinical studies designed to test various forms of both injected and oral insulins for diabetes, including the first ever Phase 2b study of oral liver targeted insulin and the first ever Phase 2b study of injected liver targeted mealtime insulin. In his role at Diasome, he is responsible for aligning technology, clinical, and business teams in Diasome’s work to achieve the first approved liver targeted insulin therapy. Mr. Geho received his undergraduate degree from both The Cleveland Institute of Music and Case Western Reserve University and his MBA from The Weatherhead School of Management at CWRU.

Bob Geho, Diasome - Part of the NameTag Series

Bob Geho Diasome

Bob Geho, CEO, Diasome discusses the current treatments for diabetes and the nearly 100 year history of insulin.  He talks about the company's hepatocyte directed vesicle (HDV) nanotechnology that can be added to any insulin to lessen the instances of high and low blood sugar levels in people with diabetes.  HDV nanotechnology can be added to any insulin to improve its safety and efficacy by targeting specific organs and in this case, restoring the liver's natural role in blood glucose control. #Type1Diabetes  #Type2Diabetes  #Diabetes #Insulin @diasome Diasome.com

Bob Geho, CEO, Diasome discusses the current treatments for diabetes and the nearly 100 year history of insulin.  He talks about the company's hepatocyte directed vesicle (HDV) nanotechnology that can be added to any insulin to lessen the instances of high and low blood sugar levels in people with diabetes.  HDV nanotechnology can be added to any insulin to improve its safety and efficacy by targeting specific organs and in this case, restoring the liver's natural role in blood glucose control. #Type1Diabetes  #Type2Diabetes  #Diabetes #Insulin @diasome <a href="http://diasome.com" rel="noopener nofollow" target="_blank">Diasome.com</a>

Developing Smarter Insulin to Treat Diabetes with Bob Geho Diasome